CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 60 enrolled
Drug / intervention
SARS-CoV-2 mRNA vaccine (RBMRNA-405) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05897190
NCT05897190Phase 1Completed
CompareCT.gov

Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine (RBMRNA-405) as a Booster in Chinese Adults & Older

Argorna Pharmaceuticals Co., LTD·interventional·Posted Jun 9, 2023·Updated Mar 25, 2024

In Brief

A Phase 1 clinical trial evaluating SARS-CoV-2 mRNA vaccine (RBMRNA-405) and CoronaVac® for SARS-CoV-2. Completed, enrolled 60 participants across 1 site.

Detailed Summary

This study is to evaluate the safety and immunogenicity of a SARS-CoV-2 mRNA Vaccine as a heterologous booster dose in adults who completed 2 doses of inactivated vaccination through 12 months in China.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV-2
CountriesChina
Collaborators--

Timeline

Phase 1CompletedFinished
2023202420252026
First PostedJun 9, 2023
Enrollment StartMay 16, 2022
Primary CompletionJun 13, 2022
Study CompletionMay 12, 2023
TodayJul 2, 2026
Enrollment to primary: 27 daysPosted 3.1 years ago

Interventions

SARS-CoV-2 mRNA vaccine (RBMRNA-405)biological

Dose A

CoronaVac®biological

Dose B